跳至主要内容
临床试验/NCT01940913
NCT01940913已完成2 期

Efficacy and Safety of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders.

Probi AB1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2013年10月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
发起方
Probi AB
入组人数
400
试验地点
1
主要终点
Reduction of the incidence of loose/watery stools following antibiotic treatment in children.

研究概览

简要总结

To assess the tolerability and effect of a probiotic product, when co-administered with antibiotics, on the incidence and duration of loose/watery stools following the antibiotic treatment in children.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
1 Year 至 11 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Children at the age of 1-11 years that have been ordinated to start antibiotic treatment except for penicillin.
  • •Possibility to initiate the probiotic treatment within 24 hours after the first dose of the antibiotic treatment.
  • •Children whose parents or legal caregivers have signed the informed consent to participate in the study.

排除标准

  • •Chronic intestinal disease.
  • •Current immunodeficiency or immunosuppressive treatment.
  • •Chronic or acute diarrhoeal disease.
  • •Use of laxatives the week before inclusion in the study.
  • •Antibiotic treatment for the last four weeks before inclusion in the study.
  • •Known hypersensitivity to any of the ingredients in the probiotic product or the placebo [potato starch, silicon dioxide, capsule (hypromellose, water) ± bacterial culture].
  • •Intake of any probiotic products for the last two weeks before inclusion in the study.
  • •Patient requiring hospitalisation. Lack of parents´/legal guardians´ informed consent.

研究组 & 干预措施

Probiotics

Active Comparator

干预措施: Probiotic capsules (Dietary Supplement)

Placebo

Placebo Comparator

干预措施: Placebo capsules (Dietary Supplement)

结局指标

主要结局

Reduction of the incidence of loose/watery stools following antibiotic treatment in children.

时间窗: 19-24 days

次要结局

未报告次要终点

研究者

发起方
Probi AB
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验